Chapter 31: CNS Stimulants and Attention-Deficit/Hyperactivity Disorder

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

If an orchestra is playing, you know, completely out of sync, just dozens of musicians blasting their instruments randomly, your first instinct is probably to quiet them down.

Right, you want to mute the chaos.

You certainly don't hand the conductor a megaphone and tell them to get louder.

Exactly.

It seems entirely counterintuitive.

You wouldn't introduce more noise to fix a disorganized chaotic room.

No, you really wouldn't.

But in neuropharmacology, when you are treating a hyperactive, highly distractible brain, we do exactly that.

We hand the conductor a megaphone.

Which is such a wild concept when you really stop to think about it.

It is.

So today, your mission is to master central nervous system stimulants in ADHD pharmacology.

We are doing a complete deep dive, mapping out the exact mechanisms, the pharmacokinetics and the clinical reasoning you need to safely make these really complex prescribing decisions.

And I think to start, we have to define what a central nervous system stimulant actually is, right?

Yeah, let's set the baseline.

So these molecules increase the activity of CNS neurons.

Most of them achieve this by directly enhancing neuronal excitation, while a few work by suppressing neuronal inhibition.

Okay.

But in either case, the net physiological result is just a massive increase in systemic arousal.

I want to stop right there and make a really crucial distinction.

Because when you say they increase neuronal excitation, someone might immediately think, oh, we're treating depression.

Oh, right.

Yeah, that's a common track.

Right.

But stimulants are antidepressants.

If a patient is clinically depressed, an antidepressant works selectively to elevate mood pathways.

Very specific.

Exactly.

A stimulant, on the other hand, it just dumps pure rocket fuel into the entire system.

You cannot use a stimulant to elevate a patient's mood without producing generalized systemic excitation.

And that is a vital clinical boundary.

Antidepressants are targeted.

Stimulants elevate everything indiscriminately.

Yeah.

And they cause this generalized excitation.

We really have to start by analyzing the most powerful family of stimulants, which is the amphetamines.

The heavy hitters.

Exactly.

We're talking about amphetamine, dextroamphetamine, methamphetamine, and Lisdix amphetamine.

So when you prescribe one of these, what are you actually doing at the synaptic level?

Well, you're primarily acting on the sympathetic nervous system.

Amphetamines cause this massive release of norepinephrine dopamine from the nerve terminals.

Okay.

So a huge relief.

Right.

And simultaneously,

they partly inhibit the reuptake of those exact same transmitters.

Meaning they just linger in the synapse longer.

Exactly.

They just hang around.

And this isn't isolated to the brain, by the way.

These actions take place in the CNS and throughout the peripheral nerves.

Wow.

So the profound pharmacologic effects you see in a patient are actually a direct result of all that

which totally explains the massive physiological shift.

But looking at the molecular structure in the text, there is this tiny nuance that has huge implications.

Oh, the methyl group.

Yes.

Methamphetamine is simply dextroamphetamine with just one additional methyl group attached.

Just one tiny chemical tweak.

Yeah, it's crazy.

But that one extra methyl group makes methamphetamine highly lipid soluble.

Meaning it crosses over easier.

Exactly.

It crosses the blood -brain barrier much faster and in much higher concentrations, which, you know, completely alters its abuse potential compared to other amphetamines.

That's fascinating.

But speaking of structural modifications, let's look at one designed specifically to solve a clinical problem,

Lisdex amphetamine.

Which most people probably know as Vivance.

Right.

Vivance.

I'm looking at Lisdex amphetamine and the underlying logic initially confused me a bit.

I mean, it is an amphetamine, but it's actively prescribed specifically to lower abuse potential.

Right.

It sounds like a contradiction.

Exactly.

How can an amphetamine possibly safeguard against its own abuse?

It is all in the pharmacokinetics.

Lisdex amphetamine is a pro drug.

Okay.

Let's untag that.

So the manufacturer covalently linked a molecule of dextroamphetamine to an amino acid called L -lysine.

Okay.

When those two are bonded together, the drug is completely pharmacologically inactive.

It literally does nothing.

Wait, so if someone tries to crush it up and inhale it or, you know, dissolve and inject it to get a rapid height.

It just sits there in the bloodstream.

Wow.

It does nothing.

Nothing.

For the drug to actually become active, it has to be taken orally.

Once it reaches the intestine and the liver, specific enzymes undergo a process of rapid hydrolysis.

Right.

Cleaving off that lysine molecule.

You got it.

Only then is the free, active dextroamphetamine released into the blood.

So it forces the drug into a slow, sustained release profile, which completely bypasses the sudden rush that drives abuse.

I mean, it's a brilliant pharmacological safeguard.

It really is.

But even with that delayed release, you know, you are still managing the profound systemic effects of all amphetamines.

Centrally, the patient experiences increased wakefulness, elevated mood, and suppressed appetite.

The drug even stimulates the medullary respiratory center to increase breathing.

And peripherally, that norepinephrine release hits the cardiovascular system hard.

It increases heart rate, speeds up atrioventricular conduction, increases the force of cardiac contraction,

and this is a big one, promotes profound vasoconstriction in the blood vessels.

Which is why the body adapts to that sympathetic overdrive so quickly, right?

Exactly.

With regular use, tolerance develops for the mood elevation, the appetite suppression, and those cardiovascular effects.

And this tolerance explains why the dosage numbers can become just absolutely staggering in cases of misuse.

Oh, staggering is the right word.

I mean, a non -tolerant patient might be prescribed a daily oral dose of maybe 5 to 30 milligrams.

Okay, 5 to 30.

But a highly tolerant individual suffering from severe substance use disorder might require intravenous doses of up to a thousand milligrams every few hours just to maintain euphoric effects.

Thousand milligrams?

That is unbelievable.

And when you push a human body to a 1 ,000 milligram threshold, the physical dependence is absolute.

The withdrawal isn't just a mild headache.

No, not at all.

If you abruptly withdraw amphetamines from a heavily dependent person, the intense abstin syndrome is essentially the body crashing from chronic overdrive.

You see severe exhaustion, prolonged sleep,

profound depression,

and just intense craving.

And given those powerful systemic effects, especially the vasoconstriction and the increased cardiac contractility we mentioned, clinicians are naturally highly cautious about the safety profile.

Right, which brings us to a really terrifying clinical scenario.

You're sitting there writing a prescription for a child with ADHD, and you know, these drugs slam the cardiovascular system.

Yeah, it's a heavy responsibility.

So do these drugs cause sudden cardiac death in children?

And how on earth do you handle screening before you write that script?

Well, it's one of the most heavily debated questions in pediatric pharmacology.

Back in 2008, the American Heart Association issued a statement suggesting it would be reasonable to consider an electrocardiogram, an ECG, before starting stimulants.

Okay, why did they do that?

Well, it was triggered because 14 children had died suddenly while taking Adderall.

Oh, wow.

Hearing that 14 kids died while taking a drug you're about to prescribe would make any practitioner want to ECG every single patient.

Of course it would.

But you really have to look at the broader epidemiological data.

Millions of children have used these drugs over decades.

Right.

When researchers analyzed the death rate among children taking stimulants, it is actually no greater than the sudden cardiac death rate expected in a general pediatric population of that exact same size.

Wait, really?

Yeah,

regardless of whether they take stimulants or not.

So the background rate of sudden death in the population accounts for those tragedies, not necessarily the drug itself.

Precisely.

How do you apply that to clinical practice then?

So the clinical reasoning lands here.

Routine ECGs are not necessary for every single child before starting stimulant therapy.

Good to know.

There is no evidence that universally screening asymptomatic children provides a preventative benefit.

However, and this is a hard rule, if your patient has existing evidence of heart disease or a family history of hereditary cardiovascular defects, then ordering an ECG is the only appropriate clinical decision.

So you screen based on targeted risk factors.

Exactly.

Okay, that makes sense.

That brings us to another major risk factor, which operates purely in the brain.

If a patient uses excessive amounts of amphetamines, they can enter a state of paranoid psychosis that looks almost indistinguishable from schizophrenia.

Oh yeah, we're talking severe auditory hallucinations and paranoid delusions.

It's scary.

It is.

But if we break down the neurochemistry, that makes perfect pharmacological sense.

All right.

We know the pathophysiology of schizophrenia is heavily linked to dopamine overactivity in certain brain regions.

Right.

Because amphetamines force a massive systemic release of dopamine, the drug is artificially mimicking that exact schizophrenic disease state.

And the proof is in the treatment, right?

Yep.

You can alleviate amphetamine -induced psychosis by administering a dopamine receptor blocker, like haloperidol.

But the danger doesn't always stop when the drug clears their system, does it?

Unfortunately, no.

In some highly vulnerable individuals, introducing a stimulant can actually unmask latent schizophrenia.

The hallucinations won't just fade when the amphetamine is withdrawn.

Right.

That patient will now require ongoing lifelong psychiatric care.

This is the exact reason there are strict black box warnings on these medications.

You are balancing a high potential for misuse, marked tolerance, psychological dependence, and the risk of severe psychiatric events.

So if amphetamines carry black box warnings for unmasking latent schizophrenia and massive abuse potential,

you immediately have a massive barrier to treating vulnerable patients.

Yeah.

You need an alternative.

You're forced to look for a molecule that delivers the dopamine focus without the amphetamine structure.

And structurally, methylphenidate offers exactly that loophole.

Methylphenidate, which most people know as Ritalin or Concerta, this is such a fascinating pharmacological workaround.

Is it?

Structurally, methylphenidate is entirely dissimilar to the amphetamines.

Chemically, they don't look anything alike.

Not at all.

Yet, its pharmacologic actions are practically identical.

The mechanism of action, the adverse effects, the schedule 2 abuse liability, they are completely matched.

It is basically an amphetamine in everything but structure and name.

Precisely.

It still promotes norepinephrine and dopamine release while inhibiting their reuptake.

Okay.

And just like standard amphetamine, methylphenidate is a rhizomeinic mixture.

It's a 50 -50 blend of dextro and levo isomers.

Right.

And the dextro isomer is the active component carrying almost all the pharmacologic weight while the levo isomer essentially just goes along for the ride.

Exactly.

Which perfectly explains the logic behind dexmethylphenidate.

Pharmaceutical companies simply isolated that active dextro isomer and threw away the inactive half.

Right.

They just cleaned it up.

Yeah.

Because you've stripped away the inactive filler, if you are transitioning a patient from standard methylphenidate to dexmethylphenidate, you cut the dosage exactly in half.

Yep.

It's pure, highly efficient pharmacology.

So cool.

Shifting gears slightly, let's talk about a stimulant that doesn't carry a schedule 2 warning but is by far the most widely consumed stimulant on the planet.

The methylxanthines.

Specifically, caffeine.

Ah, the morning rocket fuel.

Exactly.

I know it wakes me up.

But what is caffeine actually doing at the receptor level?

So its primary mechanism of action is the reversible blockade of adenosine receptors.

Under normal circumstances, adenosine acts as an inhibitory neurotransmitter.

It promotes sleepiness and suppresses arousal.

So by blocking those receptors, caffeine prevents that inhibition.

Exactly.

It also enhances calcium permeability in the sarcoplasmic reticulum, which aids in muscle contraction.

Oh, interesting.

But clinically, its most vital application isn't for fatigued adults.

It's actually used in the neonatal intensive care unit for treating neonatal apnea.

That is such a wild concept to wrap your head around.

It really is.

Why are we giving essentially intravenous espresso to premature infants?

Well, premature infants have underdeveloped central nervous systems.

They frequently experience prolonged apneic episodes where they simply stop breathing for 15 seconds or more.

Which is terrifying.

And it's accompanied by a drop in heart rate, or bradycardia.

This rapidly leads to hypoxemia and potential neurologic damage.

Right.

So remember how adenosine is inhibitory?

Yes.

In the brain stem, adenosine inhibits the respiratory drive.

By administering caffeine citrate, we block those adenosine receptors in the medullary respiratory center.

Which stimulates the central drive to breathe.

Exactly.

It reduces the number and duration of those apneic episodes.

That is incredible.

A drug we use to stay awake through a night shift is literally keeping premature infants breathing.

It's amazing pharmacology.

What about modafinil?

It's often grouped with these drugs, but categorized as a unique nonamphetamine.

Right.

Modafinil promotes wakefulness, but it avoids some of the heavy systemic stimulation of amphetamines.

Okay, how does it do that?

It works by inhibiting sleep -promoting neurons.

Specifically, by blocking the reuptake of norepinephrine.

It's primarily indicated for patients suffering from narcolepsy, shiftwork sleep disorder, and obstructive sleep apnea.

And because it's a nonamphetamine, it's tempting to assume it's perfectly safe, but you cannot let your guard down.

No, definitely not.

Modafinil can still increase heart rate and blood pressure,

but the biggest red flag and a massive pitfall for prescribing clinicians is its drug interactions.

Yes, this is crucial.

Modafinil actively induces the CYP3A4 hepatic isoenzyme.

And that's a big deal because if your patient is taking an oral contraceptive, Modafinil will accelerate the metabolism of that birth control.

Causing its blood levels to decline to the point of failure.

Exactly.

You have to counsel patients to use alternative non -hormonal contraception.

It is a non -negotiable piece of patient education.

Definitely.

You also have to monitor for rare but severe dermatologic reactions.

There are post -marketing reports linking Modafinil to Stevens -Johnson syndrome.

Oh, wow.

Yeah, so you must educate your patients to watch for any unexplained swelling, rash, or changes in the oral mucosa.

Especially if accompanied by a fever.

And instruct them to discontinue the drug immediately if those signs appear.

Absolutely.

Okay, so we've covered neonatal apnea and adult shift work disorder.

This proves you can't apply this pharmacology identically across a patient's entire life.

No, the physiological vulnerabilities shift drastically from the NICU to a geriatric ward.

Right.

So when you look at the entire lifespan, how does age alter your approach to stimulant therapy?

Well, you always have to match the physiological vulnerability of the life stage to the drug's safety profile.

For infants, as we discussed, only caffeine citrate is considered safe, and specifically only for neonatal apnea.

All other stimulants are contraindicated.

Correct.

Moving to children and adolescents, the stimulant class is proven safe and highly effective for ADHD.

However, we also use non -stimulants in this population, right?

Yes.

Atomoxetine is a primary non -stimulant option, but it carries a very specific, rare risk of suicidal thinking in children and adolescents that requires hypervigilant monitoring by parents.

Good to know.

What about when treating pregnant or breastfeeding patients?

The data requires caution.

Animal studies show adverse fetal effects from heavy caffeine use, though definitive human data is lacking.

And for breastfeeding.

Giving stimulants like methylphenidate at low doses doesn't typically produce reported side effects in the nursing infant.

But if the parent requires large doses, the sympathetic overdrive can actually interfere with the parent's milk production.

Fascinating.

And finally, older adults.

What happens when we introduce these drugs to a geriatric patient?

In older adults, stimulants aren't usually prescribed for hyperactivity.

They're occasionally used off -label to treat profound apathy, severe depression, and debilitating fatigue.

But the aging cardiovascular system is incredibly vulnerable to that norepinephrine surge, I'd imagine.

Oh, absolutely.

Clinicians must start at significantly lower doses and strictly avoid stimulants in patients with underlying cardiac disease or glaucoma.

Glaucoma too.

Yes.

You have to monitor their heart rate, blood pressure, and weight very, very closely.

All right.

We've mapped out the pharmacokinetics, the safety alerts, and the lifespan considerations.

Now we really need to tackle their primary clinical application.

Attention deficit hyperactivity disorder.

Yes.

The main event.

Before we treat it, what is the underlying neurobiology of an ADHD brain?

Functional neuroimaging shows us that ADHD isn't just behavioral.

It's structural and chemical.

Okay.

We see abnormalities in multiple brain areas.

The frontal cortex, the basal ganglia, the brain stem, and the cerebellum.

These are the exact regions responsible for regulating executive function, attention, impulsive behavior, and motor activity.

Exactly.

The dominant pathophysiological theory is that there is a profound dysregulation in the neuronal pathways that employ norepinephrine, dopamine, and serotonin.

Which brings us back to the paradox we opened with.

If a child's brain is highly distractible, impulsive, and physically bouncing off the walls, why are we giving them a powerful stimulant?

Let's go back to your orchestra conductor metaphor.

Right.

The frontal cortex is the conductor of the brain.

It dictates what you take attention to and suppresses background noise.

And in an ADHD brain, the conductor is understimulated and functionally asleep.

Exactly.

The musicians,

the impulses and distractions are playing loudly and chaotically.

So the stimulant doesn't sedate the rowdy musicians.

It gives the conductor the megaphone.

Stimulants increase dopamine and norepinephrine, specifically in those frontal cortex pathways waking the conductor up.

The impulsiveness and hyperactivity decline because the frontal cortex finally has enough neurotransmitter to concentrate on the task at hand and suppress the background noise.

The stimulant removes the neurological impediment of severe distractibility.

It provides the focus.

But the data reveals a very sobering reality about this treatment.

Yeah, it does.

While the initial response can be life -changing, dramatically improved attention,

better tests of memory, improved reading comprehension,

those profound benefits often plateau and diminish after two to three years of continuous therapy.

Which really forces us to reframe how we view the medication.

Stimulants are not a permanent cure.

They are best utilized to buy time.

They create a neurochemical window of focused calm where clinicians, educators and families can actively teach the child long -term behavioral strategies, coping mechanisms and study skills.

And managing that window of therapy requires precise clinical decision making, specifically regarding adverse effects.

Because you're inducing wakefulness, insomnia is a primary issue.

A huge issue.

To prevent it, clinicians advise taking no daily doses after 4 .00 p .m.

Furthermore, because stimulants suppress the appetite center in the brain, they can cause significant weight loss and subsequent growth suppression in children.

Which is very concerning for parents.

Of course.

To mitigate this, stimulants should be administered during or immediately after meals rather than on an empty stomach.

Clinicians also frequently utilize drug holidays.

Taking breaks from the meds.

Right.

By intentionally pausing the medication on weekends or over summer vacations, you allow the child's appetite to fully return.

This creates an opportunity for rebound growth to catch up, ensuring their final adult height likely won't be negatively affected by the years of therapy.

Exactly.

It's all about balance.

But we know that up to 33 % of patients fail to respond adequately to stimulants or simply can't tolerate the insomnia and anorexia.

Right.

Combine that with the very real concerns about abuse liability and clinicians absolutely need a second line defense.

That brings us to the non -stimulants.

The two primary non -stimulants are adamoxetine and valoxazine.

Okay.

Because they operate through entirely different mechanisms, they are not regulated as controlled substances.

This means there is zero abuse potential and prescriptions can be easily called in and refilled over the phone.

That's a huge logistical advantage.

But if adamoxetine isn't dumping dopamine and norepinephrine into the system like rocket fuel, how does it actually treat ADHD?

Adamoxetine is a highly selective norepinephrine reuptake inhibitor.

Okay, so it binds to the reuptake transporters and blocks them.

Yes, causing a steady accumulation of norepinephrine at the synapses.

But because it lacks that massive initial release mechanism that amphetamines have,

the clinical timeline is entirely different.

Meaning it's not immediate.

Exactly.

While a stimulant works almost immediately within an hour, adamoxetine's initial response takes a few days to become noticeable.

And the maximal therapeutic response takes one to three weeks to fully develop.

Right, it's a slow, steady build.

But pharmacokinetically, adamoxetine presents a unique challenge for the prescriber.

It is metabolized in the liver primarily by the CYP2D6 isoenzyme.

And genetic variations mean about 5 to 10 percent of patients are slow metabolizers because they possess an atypical sluggish form of this enzyme.

And if the enzyme can't clear the drug, the drug builds up.

For those slow metabolizers, the half -life adamoxetine jumps from a standard five hours to a massive 24 hours.

If a clinician doesn't recognize this and adjusts the dosage downward,

the patient will quickly reach toxic systemic levels.

You also have to be hyper aware of drug interactions here.

Right.

If a patient is prescribed a CYP2D6 inhibitor, like the common antidepressants, peroxetine or floxetine,

those drugs will shut down the enzyme and artificially cause adamoxetine levels to spike.

Exactly.

And speaking of toxicity, we have to mention the liver injury warning.

Oh, definitely.

Adamoxetine carries a small but very real risk for severe liver injury that can progress to outright liver failure.

So you must educate your patients to report signs of jaundice, dark urine or unexplained right upper quadrant pain immediately.

Yes, immediately.

We also briefly need to mention the other class of non -stimulants used for ADHD.

The alpha two adrenergic agonists, specifically guanfacine and clonidine.

Now that seems a bit confusing.

Clonidine is a blood pressure medication.

How does lowering blood pressure help a distractible brain?

Well, it acts on alpha two receptors in the central nervous system.

But clinically, what's most important is how their side effect profile contrasts with stimulants.

They don't cause insomnia or anorexia.

In fact, their principal side effects are sedation and hypotension.

Which gives a clinician incredible flexibility.

Right.

If you have a patient whose primary issue is severe aggression and insomnia, a stimulant might make things way worse.

Exactly.

But guanfacine could provide the behavioral control while actually helping them calm down.

It's all about matching the drug's side effect profile to the patient's specific physiological needs.

Which perfectly transitions to the final major clinical decision, selecting the right formulation.

When you look at the dosing charts for ADHD medications like table 31 .1 in the text, you are confronted with immediate release, sustained release, and 24 -hour formulations.

That's a lot of options.

How does a clinician practically decide between them in the real world?

Rational drug selection is really about matching the drug's duration of action to the rhythm of the patient's daily life.

Immediate release options last roughly three to five hours.

That means a child requires two or three daily doses.

Which inevitably leads to midday school interruptions and daily trips to the school nurse's office.

Which is highly disruptive.

It singles the child out and it relies on school staff to ensure compliance.

Exactly.

That's why we heavily rely on sustained release or 24 -hour osmotic release systems like Concerta or even the transdermal detrana patch.

You select the formulation that provides steady uninterrupted baseline coverage exactly when the patient needs focus during school or work hours.

While ensuring the drug tapers off predictably in the late afternoon to avoid night time insomnia.

It really is precision engineering for the brain's daily schedule.

It absolutely is.

Which leaves us with a highly provocative question to consider.

We noted earlier that the profound physiological benefits of stimulants for ADHD tend to plateau after two to three years of use.

Right, the brain adapts.

If that is true, what does that mean for the estimated 8 million adults in the United States who currently have undiagnosed and entirely untreated ADHD?

It's a huge question.

It severely underscores the reality that handing the conductor a megaphone is merely the bridge to cognitive and behavioral adaptation.

It is not the final destination.

No, it's not.

The medication simply buys you the time and the clarity to build the behavioral habits that will actually sustain you for a lifetime.

It's an essential perspective for any practitioner to keep in mind when writing that prescription.

The pharmacology is the tool, not the cure.

That brings us to the end of our chapter analysis.

Thank you for joining us for this deep dive.

You're making clinical decisions that alter brain chemistry and we hope this breakdown of the mechanisms and the prescribing logic helps you make those calls safely.

Absolutely.

On behalf of the Last Minute Lecture team, we wish you the absolute best in your advanced practice studies.

Keep analyzing, keep asking why, and we'll see you next time.